Senescent-cell survival
Some senescent cells use FOXO4 to retain p53 in nuclear structures, helping them resist apoptosis.
Back to Peptide Library
Experimental Senolytic
FOXO4-DRI
D-Retro-Inverso Peptide • FOXO4–p53 Research
FOXO4-DRI is designed to disrupt a survival mechanism in some senescent cells. Cell and mouse experiments drew attention to it, but no human trial has established a safe or effective dose, selectivity, or long-term outcome.
At a glance
FOXO4-DRI Quick Reference
- Daily approach
- 250–500mcgAnecdotal escalation over 16 weeks
- Pulse approach
- 3mg EODThree reported doses over six days
- Target
- FOXO4–p53Proposed senescent-cell apoptosis
- Evidence
- PreclinicalNo validated human protocol
Overview
What Is FOXO4-DRI?
FOXO4-DRI is a synthetic D-retro-inverso peptide investigated as a senolytic: a compound intended to eliminate some senescent cells. These cells have stopped dividing but can remain active, releasing inflammatory and tissue-remodeling signals called the senescence-associated secretory phenotype, or SASP.
In certain senescent cells, FOXO4 binds the tumor-suppressor protein p53 and helps the cells resist apoptosis. FOXO4-DRI competes with that binding, allowing p53 to move toward the cytosol and trigger caspase-dependent cell death. The retro-inverso design uses D-amino acids to improve resistance to enzymatic breakdown.
The original 2017 study reported selective effects in the tested senescent-cell models and improvements in fur, activity, and kidney measures in mice. Later mouse work explored pulmonary fibrosis and aged Leydig cells. These are important preclinical observations, but human selectivity, exposure, immune effects, and clinical benefit have not been established.
Mechanism
FOXO4-DRI Mechanism of Action
FOXO4–p53 disruption
FOXO4-DRI competes with the binding interaction in experimental systems.
Apoptotic response
Released p53 can move toward the cytosol and trigger caspase-3/7-associated apoptosis in tested cells.
Selectivity limit
The original selectivity results were model-specific; off-target effects and tissue outcomes in humans are unknown.
Research findings
FOXO4-DRI Benefits
Every outcome below comes from cells or animals. None is a demonstrated human treatment benefit.
Senescent-Cell Models
The original work reduced viability of certain senescent cells by disrupting FOXO4–p53 binding.
Tissue Homeostasis
Short-course mouse experiments reported changes in fur density, activity, and kidney-function measures.
Inflammation Research
Clearing some senescent cells may reduce SASP-related signaling, though benefit depends on cell type and tissue context.
Pulmonary Fibrosis Models
Mouse studies found reduced fibrosis-related changes after FOXO4-DRI exposure; this is not evidence of a human lung treatment.
Leydig-Cell Models
Aged-mouse research reported partial improvement in testosterone secretion after targeting senescent Leydig cells.
Chemotoxicity Models
The original mouse study reduced aspects of doxorubicin-related toxicity; it does not establish safety during human cancer therapy.
Protocol planning
FOXO4-DRI Dosing Protocol
Two very different SubQ schedules circulate in the community: a long daily escalation and a brief pulse. Neither has a human dose-finding or safety trial, and animal dosing cannot supply a human starting dose.
Members Access Only
Sign in or create a free account to view this content.
Preparation
FOXO4-DRI Reconstitution
Example concentration
10mg vial + 2mL bacteriostatic water
Result5mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
2
Add diluent slowly
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
3
Dissolve gently
Swirl or roll the vial until the contents dissolve; do not shake.
4
Store
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
FOXO4-DRI Community Experience
Positive Reports
- A small number of users describe improved energy, recovery, or less inflammation after a cycle; reports are inconsistent and usually involve other changes.
Negative & Mixed Reports
- Injection-site burning, itching, redness, or swelling is frequently mentioned.
- Many users notice no immediate effect.
- Fatigue, headache, or flu-like sensations appear in scattered reports.
Stacking & synergy
FOXO4-DRI Stacking & Synergy
All of these are theoretical or community-discussed pairings. Combination safety and outcomes have not been tested in people.
FOXO4-DRI + Epitalon
A proposed “clear and rebuild” sequence across senescence and telomere research; no human study supports it.
FOXO4-DRI + SS-31
Senescent-cell clearance and mitochondrial support are different hypotheses, with unknown combined effects.
FOXO4-DRI then MOTS-c
Some users discuss a metabolic-support phase after a pulse; the sequence is unvalidated.
Other Senolytics
Adding fisetin, quercetin, dasatinib, or other senolytics can make effects harder to predict and attribute.
Safety notes
FOXO4-DRI Side Effects & Safety
Mouse tolerability findings cannot establish human safety. No completed human program defines acute toxicity, immune response, organ effects, reproductive risk, or repeated-course outcomes.
Immediate Reports
- Injection-site burning, itching, redness, or swelling.
- Fatigue, headache, or flu-like sensations.
- Possible allergic or inflammatory reactions.
Major Unknowns
- Off-target apoptosis in healthy or useful cell populations.
- Unexpected effects of repeated FOXO4–p53 manipulation.
- Immunogenicity, contamination, endotoxin exposure, or incorrect concentration in research products.
FOXO4-DRI Precautions
Do Not Use If You Have
- Pregnancy or breastfeeding, where reproductive safety data are absent.
- Active or suspected cancer, or current chemotherapy or radiation, without oncology supervision.
- Known hypersensitivity to FOXO4-DRI or a formulation component.
Use Extreme Caution With
- History of cancer, bone-marrow or immune disorders, or immunosuppressive treatment.
- Severe kidney or liver impairment.
- Other senolytic drugs or research compounds.
FOXO4-DRI is not FDA approved and has no established human dose, prescribing information, or confirmed therapeutic use.
Final verdict
Peptide Protocols Verdict on FOXO4-DRI
Our opinionated opinion
FOXO4-DRI is one of the most provocative senolytic ideas we have covered. The cell and mouse work is interesting, and we understand why experienced researchers follow it. Even so, we are deliberately staying away from it and will not test it in-house.
Our concern is the uncertainty around which cells it clears and what repeated manipulation of the FOXO4–p53 pathway might do. There is no human safety program to resolve that concern, and a report of better energy after a cycle is too thin a reason for us to recommend it. For now, it remains a D in our book.